SCHEMBL13020484

SCHEMBL13020484

Nc1ncnc2c1ncn2C1OC(CO)CC1OP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)C(OP(=O)(S)OCC2OC(n3cnc4c(N)ncnc43)C(O)C2O)C1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RNASEL Q05823 11/20 0.65
▸ P2RY1 P47900 4/20 0.61
▸ P2RY2 P41231 3/20 0.61
▸ SRC P12931 2/20 0.61
▸ ADORA1 P30542 2/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ DNPH1 O43598 1/20 0.61
▸ PRKAB2 O43741 1/20 0.61
▸ TRPM2 O94759 1/20 0.61
▸ LDHA P00338 1/20 0.61
▸ ADRB2 P07550 1/20 0.61
▸ FBP1 P09467 1/20 0.61
▸ PRKAG1 P54619 1/20 0.61
▸ PRKAA2 P54646 1/20 0.61
▸ PDE4D Q08499 1/20 0.61
▸ KCNH2 Q12809 1/20 0.61
▸ PRKAA1 Q13131 1/20 0.61
▸ PDE3A Q14432 1/20 0.61
▸ TAS1R3 Q7RTX0 1/20 0.61
▸ TAS1R1 Q7RTX1 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020769 0.95 P2RY1 (0.65) RNASELP2RY1P2RY2SRCADORA1
SCHEMBL13020481 0.94 P2RY1 (0.58) RNASELP2RY1P2RY2SRCADORA1
SCHEMBL12963356 0.91 P2RY1 (0.60) RNASELP2RY1P2RY2SRCADORA1
SCHEMBL22326769 0.91 RNASEL (0.73) RNASELP2RY1P2RY2SRCADORA1
SCHEMBL13020487 0.91 RNASEL (0.73) RNASELP2RY1P2RY2SRCADORA1
SCHEMBL24239209 0.88 FUT5 (0.58) P2RY1P2RY2SRCADORA1SMN1; SMN2
SCHEMBL18521558 0.88 FUT5 (0.58) P2RY1P2RY2SRCADORA1SMN1; SMN2
SCHEMBL18510962 0.88 FUT5 (0.58) P2RY1P2RY2SRCADORA1SMN1; SMN2
SCHEMBL18521167 0.88 FUT5 (0.58) P2RY1P2RY2SRCADORA1SMN1; SMN2
SCHEMBL18521636 0.88 FUT5 (0.58) P2RY1P2RY2SRCADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2010-12-30 — — US disclosed
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE ALIOS BIOPHARMA, INC. (US) 2010-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331397-A1 2-5A ANALOGS AND THEIR METHODS OF USE RNASEL, RNASE1, RNASEH1 RNASEL 1/4885P2RY1 3036/4885P2RY2 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback